<DOC>
	<DOCNO>NCT02966834</DOCNO>
	<brief_summary>This study conduct evaluate efficacy , safety tolerability GSK2330672 administration treatment pruritus ( itch ) participant primary biliary cholangitis ( PBC ) . Participants treat either placebo one 4 dose regimen GSK2330672 ( 20 milligram [ mg ] , 90 mg 180 mg take daily 90 mg twice daily ) . Subjects GSK2330672 also receive placebo tablet maintain blinding . The total duration subject 's participation 45 day screen 24 week study include follow-up .</brief_summary>
	<brief_title>Dose Response Study GSK2330672 Treatment Pruritus Patients With Primary Biliary Cholangitis</brief_title>
	<detailed_description />
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Cholangitis</mesh_term>
	<criteria>Inclusion Criteria Participant must 18 80 year age inclusive , time signing informed consent . Participants proven PBC , demonstrate least 2 follow : History sustain increase ALP level &gt; ULN first recognize least 6 month prior Screening Visit ( Note : Sustained ALP elevation time Screening require , recognize ALP may decrease institution ursodeoxycholic acid ( UDCA ) therapy describe inclusion number 4 ) . Documented positive antimitochondrial antibody ( AMA ) titer ( &gt; 1:40 titer immunofluorescence M2 positive enzymelinked immunosorbent assay ) PBCspecific antinuclear antibody ( antinuclear dot nuclear rim positive ) . Liver biopsy ( time past ) consistent PBC . Participants must rate itch severity &gt; =4 0 10 point scale majority time 8 week prior Screening Visit . Participants currently take UDCA stable dos UDCA &gt; 8 week time screen . Participants take UDCA due intolerance may enrol 8 week last dose UDCA . No change discontinuation permit completion Main Study Period . Male and/or female : Female participant A female participant eligible participate pregnant , breastfeeding , least one follow condition applies : Not woman childbearing potential ( WOCBP ) WOCBP agree follow contraceptive guidance treatment period least 4 week last dose study treatment . Capable give sign informed consent , include compliance requirement restriction list informed consent form ( ICF ) protocol . Exclusion Criteria Screening total bilirubin &gt; 1.5x ULN . Isolated bilirubin &gt; 1.5x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % . Screening ALT AST &gt; 4x ULN . Screening eGFR &lt; 45 milliliter ( mL ) /minute/1.73 meter square ( m^2 ) base CKDEPI . History presence hepatic decompensation ( e.g. , variceal bleeds , encephalopathy ascites ) . History presence concomitant liver diseases include hepatitis due hepatitis B C virus ( HBV , HCV ) infection , primary sclerosing cholangitis ( PSC ) , alcoholic liver disease , definite autoimmune hepatitis , biopsy proven nonalcoholic steatohepatitis ( NASH ) confirm hepatocellular carcinoma . Current symptomatic inflammatory bowel disease , chronic diarrhea , Crohn 's disease diarrhea relate malabsorption syndrome . Current symptomatic cholelithiasis inflammatory gall bladder disease . Participants history cholecystectomy &gt; =3 month screen may eligible enrolment . Any current medical condition ( e.g . psychiatric disorder , senility dementia ) , may affect participant 's ability comply protocol specify procedure . Administration follow drug time 3 month prior screen study plan administration study : colchicine , methotrexate , azathioprine , systemic corticosteroid . Initiation increase dose bezafibrate fenofibrate time 3 month prior screen . Participants may join study stable dos medication , change discontinuation permit completion Main Study Period . Initiation increase dose follow 8 week prior screen : rifampicin , naltrexone , naloxone , nalfurafine , sertraline . Participants may join study stable decreased dos medication , change dose permit completion Main Study Period . Bile acid bind resin use : participant must discontinue use cholestyramine , colesevelam , colestipol colestimide prior start Initial Study Period ( later Day2 ) . Note : drug may administer completion Main Study Period , clinically indicate . Obeticholic acid use : participant must discontinue use obeticholic acid least 8 week prior start Initial Study Period may restart end study . Current enrolment participation within 8 week start Initial Study Period , clinical study involve investigational study treatment . QT interval correct heart rate QTc &gt; 450 millisecond ( msec ) QTc &gt; 480 msec participant bundle branch block History sensitivity study treatment component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation study . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram alcohol : halfpint ( ~240 mL ) beer , 1 glass ( 125 mL ) wine 1 measure ( 25 mL ) spirit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PBC</keyword>
	<keyword>itch</keyword>
	<keyword>GSK2330672</keyword>
	<keyword>GLIMMER</keyword>
	<keyword>primary biliary cholangitis</keyword>
	<keyword>pruritus</keyword>
</DOC>